Virpax to pursue over-the-counter pathway for topical spray treatment for osteoarthritis pain

Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it will pursue a direct to over-the-counter (OTC) regular pathway for Epoladerm.

Berwyn, Pennsylvania-based Virpax designed the Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering

Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million.

Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0